We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




SuperNova Diagnostics Enters Agreement with KSB Diagnostics of China

By LabMedica International staff writers
Posted on 23 Mar 2011
SuperNova Diagnostics, Inc. More...
(Germantown, MD, USA; and London, United Kingdom), a privately-held global diagnostics company for human and nonhuman health applications, signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology Co., Ltd. (KSB; Shenzhen, China), a biotechnology diagnostics company specializing in research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and affiliated markets. Financial terms of the agreement were not disclosed.

AmpCrystal, SuperNova Diagnostics' lead technology with multiple product formats, allows minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes. It can detect directly unamplified DNA in human, animal, or environmental samples. AmpCrystal is hyper-dense, energy-mediated nanocrystals that can be utilized in a wide variety of diagnostic applications and configurations. The technology platform lends itself to both forward-integration into new product formats as well as backward compatible into existing open and closed diagnostic systems.

With three integrated capabilities (sample collector/processor, analytical disposable, and the readout device), AmpCrystal technology is simpler, more robust, faster, and significantly less expensive than existing POC systems.

A powerful nanochemistry, AmpCrystal, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without polymerase chain reaction (PCR) with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtiter, microarrays, closed systems, research products, and OEM).

"We are delighted to announce this agreement with KSB Diagnostics, a leader in China and Asia for diagnostics," said Neil Campbell, president & CEO of SuperNova Diagnostics. "This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets."

Through cooperation with its worldwide partners and introduction of advanced technology in the world, Shenzhen Kang Sheng Bao Bio-Technology Co. Ltd. provides the innovating diagnostic kits. Its goals are to make great efforts to serve the rapidly developing market in China and become one of the well-known corporations in the field of in vitro diagnostic reagents.

Related Links:
SuperNova Diagnostics, Inc.
Kang Sheng Bao Bio-Technology Co., Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.